Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – Should You Sell?

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares gapped down prior to trading on Monday . The stock had previously closed at $7.69, but opened at $6.88. Telix Pharmaceuticals shares last traded at $6.9250, with a volume of 88,006 shares trading hands.

Analyst Upgrades and Downgrades

TLX has been the topic of a number of research analyst reports. Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Tuesday, January 27th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Finally, Wall Street Zen downgraded Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Telix Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Telix Pharmaceuticals Price Performance

The firm has a 50 day simple moving average of $7.51 and a two-hundred day simple moving average of $9.23. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.22 and a current ratio of 1.33.

Telix Pharmaceuticals (NASDAQ:TLX) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.06). The company had revenue of $414.02 million during the quarter, compared to analyst estimates of $421.50 million. As a group, analysts predict that Telix Pharmaceuticals Limited will post 0.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Telix Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers increased its position in Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Telix Pharmaceuticals during the fourth quarter worth $89,000. IHT Wealth Management LLC acquired a new position in shares of Telix Pharmaceuticals during the second quarter worth $213,000. OLD Mission Capital LLC bought a new position in shares of Telix Pharmaceuticals in the 4th quarter valued at $111,000. Finally, Private Advisor Group LLC boosted its holdings in shares of Telix Pharmaceuticals by 67.3% during the 3rd quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock valued at $403,000 after acquiring an additional 16,945 shares in the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.